Merck (MRK) Depreciation & Amortization (CF) (2009 - 2026)

Merck has disclosed Depreciation & Amortization (CF) across 18 years of filings, most recently posting $581.0 million for Q1 2026.

• In Q1 2026, Depreciation & Amortization (CF) rose 15.74% year-over-year to $581.0 million; the TTM figure through Mar 2026 stood at $2.5 billion (up 115.87% YoY), while the FY2025 annual figure was $3.0 billion, up 45.0% from the prior year.
• Depreciation & Amortization (CF) eased to $581.0 million in Q1 2026, from $1.5 billion in the prior quarter.
• Over the last five years, Depreciation & Amortization (CF) for MRK reached as high as $1.5 billion in Q4 2025 and fell as low as $1.0 million in Q3 2025.
• The 5-year median for Depreciation & Amortization (CF) is $448.0 million (2022), against an average of $451.2 million.
• The widest YoY moves for Depreciation & Amortization (CF): up 579.1% in 2025, down 98.82% in 2025.
• A 5-year view of Depreciation & Amortization (CF) shows it stood at $430.0 million in 2022, then climbed by 16.74% to $502.0 million in 2023, then grew by 3.19% to $518.0 million in 2024, then soared by 188.22% to $1.5 billion in 2025, then tumbled by 61.09% to $581.0 million in 2026.
• According to Business Quant data, Depreciation & Amortization (CF) over the past three periods registered $581.0 million, $1.5 billion, and $1.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.